Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma

The novel Bruton's tyrosine kinase inhibitor ibrutinib has demonstrated high response rates in B-cell lymphomas; however, a growing number of ibrutinib-treated patients relapse with resistance and fulminant progression. Using chemical proteomics and an organotypic cell-based drug screening assa...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Xiaohong, Lwin, Tint, Silva, Ariosto, Shah, Bijal, Tao, Jiangchuan, Fang, Bin, Zhang, Liang, Fu, Kai, Bi, Chengfeng, Li, Jiannong, Jiang, Huijuan, Meads, Mark B., Jacobson, Timothy, Silva, Maria, Distler, Allison, Darville, Lancia, Zhang, Ling, Han, Ying, Rebatchouk, Dmitri, Di Liberto, Maurizio, Moscinski, Lynn C., Koomen, John M., Dalton, William S., Shain, Kenneth H., Wang, Michael, Sotomayor, Eduardo, Tao, Jianguo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5399304/
https://www.ncbi.nlm.nih.gov/pubmed/28416797
http://dx.doi.org/10.1038/ncomms14920

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5399304/
https://www.ncbi.nlm.nih.gov/pubmed/28416797
http://dx.doi.org/10.1038/ncomms14920

Ejemplares similares